ストックスクリーナーアプリを入手
0.6109
2.55%
0.0198
アフターアワーズ：
.61
-0.0009
-0.15%
前日終値:
$0.5911
開ける：
$0.61
24時間の取引高:
631.32K
Relative Volume:
0.74
時価総額：
$73.69M
収益：
-
当期純損益:
$-30.54M
株価収益率:
-0.3941
EPS:
-1.55
ネットキャッシュフロー:
$-18.30M
1週間 パフォーマンス:
+6.35%
1か月 パフォーマンス:
-6.54%
6か月 パフォーマンス:
-10.58%
1年 パフォーマンス:
-27.46%
1日の値動き範囲:
$0.5951
$0.62
1週間の範囲:
$0.541
$0.62
52週間の値動き範囲:
$0.202
$0.9598
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
名前
Unicycive Therapeutics Inc
セクター
電話
650-384-0642
住所
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
UNCY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
0.6109 | 72.38M | 0 | -30.54M | -18.30M | -1.55 |
|
ONC
Beigene Ltd Adr
|
240.41 | 25.61B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.28 | 114.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 41.82M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.43 | 66.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
73.93 | 6.36B | 0 | -153.72M | -103.81M | -2.00 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-21 | 開始されました | Guggenheim | Buy |
| 2024-04-04 | 開始されました | Piper Sandler | Overweight |
Unicycive Therapeutics Inc (UNCY) 最新ニュース
Unicycive Therapeutics (NASDAQ:UNCY) Upgraded to “Strong-Buy” at HC Wainwright - Defense World
Unicycive Therapeutics (UNCY): HC Wainwright & Co. Sets Price Target | UNCY Stock News - GuruFocus
Unicycive Therapeutics CEO Shalabh Gupta to Present at Upcoming Investor Conferences - Nasdaq
Unicycive Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire
Unicycive Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire Inc.
Benchmark maintains $3 target on Unicycive stock post-Q1 filings By Investing.com - Investing.com Canada
Unicycive Therapeutics Updates Annual Meeting Time - TipRanks
Unicycive Therapeutics (UNCY) Alters 2025 Shareholder Meeting Time | UNCY Stock News - GuruFocus
Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders - GlobeNewswire
Unicycive Therapeutics Updates Annual Meeting Schedule: Key Details for Kidney Disease Biotech Investors - Stock Titan
These Numbers Show Just How Powerful Unicycive Therapeutics Inc (NASDAQ: UNCY) Stock Is - Stocksregister
Q2 Earnings Forecast for UNCY Issued By Noble Financial - Defense World
Data-Based Analysis Of Unicycive Therapeutics Inc (UNCY) - Stocksregister
Unicycive (UNCY) Advances Toward FDA Approval for Key Kidney Disease Drug | UNCY Stock News - GuruFocus
Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Unicycive Reports Strong Q1 Results as Game-Changing Kidney Drug Nears FDA Decision Date - Stock Titan
Unicycive Therapeutics, Inc. SEC 10-Q Report - TradingView
Unicycive Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Unicycive Therapeutics (UNCY) Projected to Post Quarterly Earnings on Monday - Defense World
Analysts Expect Breakeven For Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Before Long - Yahoo Finance
Geode Capital Management LLC Acquires 122,089 Shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) - Defense World
Insider’s View: Deciphering Unicycive Therapeutics Inc (UNCY)’s Financial Health Through Ratios - DWinneX
Unicycive Therapeutics Inc (UNCY)’s stock performance: a year in review - uspostnews.com
XTX Topco Ltd Raises Stock Position in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) - Defense World
Ratios Uncovered: Breaking Down Unicycive Therapeutics Inc (UNCY)’s Trailing Twelve Months Metrics - DWinneX
What is the investor’s view on Unicycive Therapeutics Inc (UNCY)? - uspostnews.com
Guggenheim Begins Coverage on Unicycive Therapeutics (NASDAQ:UNCY) - The AM Reporter
Unicycive Therapeutics (NASDAQ:UNCY) Coverage Initiated by Analysts at Guggenheim - Defense World
Guggenheim Initiates Coverage of Unicycive Therapeutics (UNCY) with Buy Recommendation - Nasdaq
Guggenheim Initiates Unicycive Therapeutics at Buy With $6 Price Target - marketscreener.com
Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update - ADVFN
HC Wainwright Reiterates “Buy” Rating for Unicycive Therapeutics (NASDAQ:UNCY) - Defense World
H.C. Wainwright maintains Unicycive Buy rating, $7.50 target By Investing.com - Investing.com Canada
Unicycive Therapeutics: Buy Rating on Imminent FDA Approval and Market Potential of Oxylanthanum Carbonate - TipRanks
Unicycive Presents New Patient-Level Data Underscoring Challenges Faced with Current Phosphate Binders and Highlighting the Potential of Oxylanthanum Carbonate to Address Barriers to Adherence for Patients with Hyperphosphatemia on Dialysis - GlobeNewswire
Breakthrough: Unicycive's New Kidney Drug Cuts Pills in Half, 98% of Patients Report Easy Use - Stock Titan
Unicycive Therapeutics Inc Inc. (UNCY) Price Performance: A Technical Analysis Perspective - investchronicle.com
60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R) - ACCESS Newswire
HC Wainwright Issues Pessimistic Estimate for UNCY Earnings - Defense World
UNCY FY2025 EPS Lifted by Brookline Capital Management - Defense World
Brookline Capital Management Weighs in on UNCY Q1 Earnings - Defense World
HC Wainwright Issues Positive Forecast for Unicycive Therapeutics (NASDAQ:UNCY) Stock Price - Defense World
Unicycive stock target raised to $7.50 by H.C. Wainwright - Investing.com Canada
Unicycive Therapeutics (NASDAQ:UNCY) Posts Quarterly Earnings Results, Misses Estimates By $0.13 EPS - MarketBeat
Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Exclusive Look: Unicycive Unveils Latest Kidney Disease Breakthroughs at Major Healthcare Conference - Stock Titan
Unicycive Therapeutics, Inc. SEC 10-K Report - TradingView
Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
FDA to Review Unicycive's Kidney Disease Drug in June 2025: Key Financial Updates - Stock Titan
Unicycive Approaches Its First Approval, But In A Competitive Space - insights.citeline.com
Targeting Pressing Unmet Needs in Kidney Diseases with Unicycive Therapeutics CEO Dr. Shalabh Gupta - iHeart
Unicycive Therapeutics Inc (UNCY) 財務データ
収益
当期純利益
現金流量
EPS
9.13%
1.64%
大文字化:
|
ボリューム (24 時間):